21 citations
,
April 2011 in “Epilepsia” The drug combination significantly reduced epileptic drop attacks in patients.
20 citations
,
December 2016 in “Neurodegenerative disease management” Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
1 citations
,
April 2022 in “The Journal of Urology” Both penicillamine and tiopronin have significant side effects, but trying the alternative drug can be beneficial if the first is not tolerated.
8 citations
,
April 2020 in “Journal of The American Academy of Dermatology” Bicalutamide may be a promising alternative treatment for female pattern hair loss.
August 2025 in “Journal of the American Academy of Dermatology” 2 citations
,
January 2012 in “PubMed” Mycophenolate mofetil is effective for treating severe lupus nephritis in children.
10 citations
,
October 2016 in “Epilepsy & behavior” Levetiracetam often causes behavioral issues, while oxcarbazepine is more likely to cause sleepiness in epilepsy patients.
64 citations
,
March 1989 in “PubMed” Valproate is effective for epilepsy but has side effects and requires careful monitoring.
September 2013 in “Neurodegenerative disease management” Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.
7 citations
,
September 2007 Valproate sustained-release is effective and generally safe for short-term treatment of new partial epilepsy.
90 citations
,
January 1989 in “PubMed” 3 citations
,
April 2021 in “Oncology Times” Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
26 citations
,
January 2005 in “PubMed” RUM-loaded SLN shows promise for treating acne and hair loss topically.
June 2025 in “British Journal of Dermatology” Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.
137 citations
,
December 2006 in “Arthritis Research & Therapy” Mycophenolate mofetil is safer and more effective than cyclophosphamide for treating lupus nephritis.
1 citations
,
December 2024 in “ACS Biomaterials Science & Engineering”
January 2025 in “Cermin Dunia Kedokteran” Choose anti-epileptic drugs carefully for women of childbearing age to avoid risks during pregnancy.
24 citations
,
July 1983 in “Clinical and Experimental Dermatology” Tigason improved hair growth in a boy with monilethrix without side effects.
March 2002 in “Reactions Weekly” Some birth control pills increase blood clot risk; use them for specific conditions only.
48 citations
,
February 1999 in “PubMed” Finasteride, a drug, can block the seizure-preventing effects of a hormone called progesterone in mice.
13 citations
,
October 2010 in “Seizure” Extended-release valproate effectively reduced seizures and improved quality of life in epilepsy patients over 6 months, with some side effects.
59 citations
,
October 1976 in “Acta Neurologica Scandinavica” Sodium valproate reduced seizures in many patients with resistant epilepsy.
6 citations
,
April 2019 in “Russkij žurnal detskoj nevrologii” Some epilepsy drugs can cause reproductive and cosmetic side effects in women and affect pregnancy, but most women still have healthy babies.
January 2004 in “Data Archiving and Networked Services (DANS)” Finasteride blocks progesterone's effect on brain activity linked to epilepsy.
65 citations
,
February 2015 in “Neuro-Oncology” Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.
4 citations
,
July 2024 in “Pharmacology Research & Perspectives” Ritlecitinib is safe and may effectively treat alopecia areata.
21 citations
,
February 2005 in “Epilepsy & Behavior” Reducing 3α,5α-THP in the hippocampus increases seizures in female rats.
4 citations
,
January 2019 in “PubMed” Low dose valproate in epileptic children mainly causes weight gain and other non-life-threatening side effects.
1 citations
,
May 2025 in “Journal of the Indian Chemical Society” 86 citations
,
June 2018 in “Cochrane library” Mycophenolate mofetil may improve lupus nephritis remission more than cyclophosphamide but with uncertain safety.